Key takeaways

• AI is moving from experimentation to execution
• The strongest use cases are tied to clear ROI
• Workflow optimization is delivering value faster than moonshot bets
• Governance, data and operating discipline now matter more than ambition

In life sciences and healthcare, technology matters most when it improves patient outcomes.

That is why the AI conversation is changing. For the last few years, the industry has spoken about AI in terms of potential. In 2026, the conversation is becoming more grounded. The shift now is from ambition to execution.

This is an important transition. Enterprise-grade AI is not defined by the number of pilots an organization can launch. It is defined by whether AI can be embedded into real workflows in a way that is scalable, auditable and trusted. The real question is no longer whether AI has promise. The question is whether organizations can operationalize that promise in ways that create measurable business value while improving care, access and the patient experience.

The market is reflecting that shift. Deloitte’s 2026 Life Sciences Outlook found that nearly half of surveyed leaders expect accelerated digital transformation to materially shape strategy this year, but only 22% say they have successfully scaled AI and only 9% report significant returns so far. The opportunity is real. So is the execution gap.

At HCLTech, we see this next phase as a defining one. Our mission is to help life sciences and healthcare organizations create better patient outcomes. As part of that mission, we are helping clients move toward enterprise-grade AI adoption; not as a technology experiment, but as a trusted, scalable capability that can strengthen operations, support better decisions and reduce friction across the healthcare journey.

Enterprise AI starts with the value chain

In life sciences and healthcare, the most mature AI conversations are still centered around drug discovery. That is understandable. The possibility of compressing discovery timelines and accelerating innovation remains compelling, and it continues to attract investment.

But enterprise execution does not stop at discovery.

What is changing now is that organizations are now looking across the value chain, from R&D and clinical development to pharmacovigilance, regulatory safety and patient engagement and asking a harder question: where can AI create practical value now?

In many cases, the strongest answers are emerging in the context of workflow transformation.

In R&D, that may mean helping scientists navigate research and content-heavy environments faster so they can spend more time on interpretation and decision-making. In clinical and pharmacovigilance, it may mean identifying and processing adverse events more efficiently. In regulatory, it may mean accelerating document preparation, impact assessment and submission readiness. In patient-facing environments, it may mean giving clinicians time back, improving service responsiveness and reducing friction across care journeys.

That is where AI starts to matter at enterprise scale. Not as a standalone tool. As an operational capability.

The first wave of value is coming from productivity

There is still enormous excitement around AI-discovered molecules and AI-supported therapies. Over time, that will be transformative. But today, the clearest value is often coming from workflow optimization and productivity gains.

That is where the market is seeing traction. It is also where organizations are seeing value faster. Tasks that once took weeks of manual efforts are increasingly being compressed into days. Teams that were previously buried in repetitive work can focus more of their attention on judgment, exception handling and decision-making.

But in this industry, speed alone is never enough.

In a regulated environment, cycle-time reduction only matters if quality, auditability and trust are preserved alongside it. Useful speed is what matters. The kind that improves efficiency without compromising compliance. The kind that allows organizations to move faster with confidence.

That is why many successful use cases are emerging in operationally intensive functions rather than only in the most futuristic applications. AI is proving itself where there is a clear process, a clear pain point and a clear return.

What scale looks like in the real world

Scale is not a successful pilot. Scale is when digital and AI capabilities are embedded into the operating model and start delivering measurable outcomes in complex, regulated environments.

For one biotechnology company focused on neurological diseases, HCLTech helped set up a software-as-a-medical-device environment supporting 14 global clinical trials across 375 hospitals. The program supported around 1,000 patients a month, delivered response times under 20 seconds for healthcare providers and achieved 100% compliance on device shipments. This was not experimentation. It was enterprise execution in action.

For a digital health company serving people with complex chronic conditions, HCLTech built a 24/7 multilingual support model spanning patients, providers, compliance monitoring and device management. The model supported more than 20 healthcare providers, enabled over 40 kit configurations and delivered more than 500 application updates. The value came not just from efficiency, but from making care delivery more responsive and reliable. In clinical trial recruitment, HCLTech supported targeted engagement and pre-screening that handled 1,000 to 5,000 consumer interactions per month while meeting service levels from day one. The impact was clear: less friction in recruitment, better participant experience and faster progress for the trial.

That is what scale looks like in the real world: not isolated innovation but trusted operational transformation that delivers measurable value.

Scaling requires more than technology

One of the clearest lessons from the last few years is that not every promising AI use case scales.

Some solutions perform well in controlled conditions but struggle when they encounter real-world complexity, fragmented data, adoption barriers or cost pressure. That is where organizations discover that scaling AI is not primarily a model challenge. It is an enterprise challenge.

That is why enterprise-scale execution demands a stronger operating model. It needs governance. It needs clear ownership. It needs data foundations. It needs cost discipline. And it needs leaders who can connect AI investment to business value, not just technical possibility.

This discipline is becoming more urgent. Forrester’s State of AI research highlights rapid adoption, but slower progress on governance, security and financial impact. Gartner has also warned that organizations without AI-ready data practices will see more than 60% of AI projects fail to deliver on business service levels and be abandoned through 2026.

The point is straightforward: ambition may open the door, but discipline is what creates enterprise value.

What scale really requires

In life sciences and healthcare, that means moving beyond technology experimentation and into operating-model transformation. It means applying AI where it can improve productivity, support decision-making, increase service responsiveness and reduce time to outcome across the value chain.

Most importantly, it means staying anchored to the purpose behind the work.

This industry exists to improve lives. To help patients get better care, better support and faster access to innovation. That is the standard enterprise AI adoption should be held to.

At HCLTech, this is how we approach the opportunity: bringing AI into life sciences and healthcare in a way that is enterprise-grade, trusted and outcome-led. Not as an end in itself, but as a practical capability that can improve decisions, reduce operational friction and help organizations deliver better experiences and outcomes for patients.

In 2026, the real differentiator is no longer ambition alone. It is execution. The ability to turn AI into a trusted enterprise capability that delivers measurable value at scale — for the business, for the workforce and ultimately for the patient.

FAQs

What does enterprise-grade AI execution look like in this industry?
It means deploying AI in real workflows with defined ownership, measurable ROI, governance controls and the ability to scale beyond a pilot.

Which AI use cases are creating the most value today?
Right now, the strongest returns are often coming from workflow-intensive areas such as research support, safety case processing, regulatory documentation, clinical operations and patient-facing support.